This startup develops advanced diagnostic technology for eye care professionals to assess corneal health. Their tools provide swift and accurate assessments, aiming to prevent eyesight loss and improve patient outcomes.
Funding
€1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing dry eye disease and early diabetes often rely on subjective assessments or invasive procedures, leading to delayed diagnoses and hindering timely intervention. Existing diagnostic approaches may also lack the ability to provide a uniform, objective metric for assessing ocular surface hydration.
Solution
Cornea Sense is developing a non-invasive technology that utilizes submillimeter-wave reflectometry and frequency domain spectroscopy to accurately measure corneal thickness and water content. This patented technology provides a direct, rapid, and objective metric for assessing ocular surface hydration, enabling earlier and more accessible screening for conditions like dry eye disease and diabetes. By establishing ocular hydration as a key indicator, Cornea Sense aims to transform chronic disease detection and facilitate proactive healthcare management. The technology aims to detect systemic and ocular diseases before complications arise.
Target Audience
The primary target audience includes eye care professionals, such as ophthalmologists and optometrists, as well as healthcare providers involved in diabetes screening and management.
Features
- Non-invasive measurement of corneal thickness and water content
- Utilizes submillimeter-wave reflectometry and frequency domain spectroscopy
- Provides a uniform, objective metric for assessing ocular surface hydration
- Technology applicable to both Dry Eye Disease and early diabetes diagnostics